Capecitabine Tablet
Product Images NDC 59651-204

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 59651-204). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aurobindo Pharma Limited, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Metabolic Pathway Of Capecitabine To 5-fu (Capecitabine Fig1)

An illustration showing the metabolic pathway of capecitabine to 5-fluorouracil (5-FU). It depicts chemical structures of capecitabine and intermediates 5'-DFCR and 5'-DFUR, with arrows labeled carboxylesterase, Cyd deaminase, and dThdPase indicating enzymatic steps leading to 5-FU formation.*

FDA Label Image

Package Label-principal Display Panel (500 mg Blister Carton (1 x 10 Unit-dose))

Packaging label for Capecitabine Tablets USP 500 mg by Aurobindo Pharma Limited. The label indicates oral tablets, packed as 10 unit-dose tablets (1 x 10). It includes the NDC 59651-205-10, manufacturer and distributor information, and notes that the batch and expiry details are printed during coding. The label features the Aurobindo logo and contact details for Aurobindo Pharma USA, Inc.*

FDA Label Image

Figure 1 Kaplan-meier Estimates Of Disease-free Survival (all Randomized Population) (Capecitabine Fig2)

A survival curve chart comparing two treatment groups: 5-FU + Leucovorin (dashed line) and Capecitabine (solid line). The y-axis represents survival probability from 0.0 to 1.0, and the x-axis shows months since randomization up to 96 months. Numbers at risk for each group are displayed below the x-axis at various time points.*

FDA Label Image

Figure 2 Kaplan-meier Estimates Of Overall Survival (all Randomized Population) (Capecitabine Fig3)

A survival curve chart comparing two treatment groups: Capecitabine and 5-FU plus Leucovorin. The chart plots survival probability on the vertical axis against months since randomization on the horizontal axis, showing the survival trends over approximately 96 months. Below, a table lists the number of patients at risk over time for each treatment group.*

FDA Label Image

Figure 3kaplan-meier Curve For Overall Survival Of Pooled Data (studies 1 And 2) (Capecitabine Fig4)

A survival curve graph comparing estimated probability over time (days) between two groups: one treated with 5-FU + Leucovorin (Mayo Regimen) and the other with intermittent Capecitabine 1250 mg/sqm twice daily. The y-axis shows estimated probability from 0 to 1, and the x-axis shows time in days up to 1500.*

FDA Label Image

Figure 4 Kaplan-meier Estimates For Time To Disease Progression Capecitabine And Docetaxel Vs Docetaxel (Capecitabine Fig5)

A survival curve chart comparing estimated probability over time (days) for two treatment groups: one with Docetaxel (100 mg/sqm every 3 weeks) and another with Capecitabine (1250 mg/sqm twice daily intermittently) combined with Docetaxel (75 mg/sqm every 3 weeks). The chart shows the survival probability declining over approximately 700 days, with arrows marking median times at 128 and 186 days for the respective groups.*

FDA Label Image

Figure 5 Kaplan-meier Estimates Of Survival Capecitabine And Docetaxel Vs Docetaxel (Capecitabine Fig6)

A survival curve chart comparing estimated probabilities over time (days) for three treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line), Capecitabine 1250 mg/sqm twice daily intermittent (solid line), and combination therapy with Docetaxel 75 mg/sqm every 3 weeks (dotted line). The y-axis shows estimated probability from 0 to 1, and the x-axis shows time in days up to 800. Vertical lines at approximately 351.5 and 442 days highlight median survival points for two groups.*

FDA Label Image

Package Label.principal Display Panel (150 mg (60 Tablets Bottle))

Label for Capecitabine Tablets USP 150 mg, oral film-coated tablets. The label states dosage strength, quantity of 60 tablets, and manufacturer as Aurobindo Pharma Limited. It includes storage instructions, distributor information (Aurobindo Pharma USA, Inc.), and a note about batch and expiry coding area. NDC 59651-204-60 is shown.*

FDA Label Image

Package Label-principal Display Panel (150 mg Blister Carton (1 x 10 Unit-dose))

Packaging label for Capecitabine Tablets USP 150 mg oral tablets by Aurobindo Pharma Limited. The package contains 10 unit-dose tablets, each film-coated and containing 150 mg capecitabine. Distributed by Aurobindo Pharma USA, Inc., the label includes NDC 59651-204-10 and indicates manufacturing in India.*

FDA Label Image

Package Label-principal Display Panel (500 mg (120 Tablets Bottle))

Label for Capecitabine Tablets USP 500 mg, oral film-coated tablets. The label shows the National Drug Code (NDC 59651-205-08), specifies each tablet contains 500 mg capecitabine USP, and indicates the package contains 120 tablets. Distributed by Aurobindo Pharma USA, Inc., made in India. Storage instructions and a barcode are also visible.*

FDA Label Image

Chemical Structure (Capecitabine Str)

Chemical structure of capecitabine, the active ingredient in the oral tablet prescription drug Capecitabine by Aurobindo Pharma Limited.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.